Skip to content
← Pheochromocytoma and Paraganglioma

HEALTH PROFESSIONAL · SOURCE READING

Other therapy

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 1, 2024 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Metastatic Pheochromocytoma / Treatment Options for Metastatic Pheochromocytoma / Palliative therapy

Other palliative treatment modalities include external-beam radiation therapy (e.g., for palliation of bone metastases) and embolization, radiofrequency ablation, or cryoablation (e.g., for palliation of bulky hepatic metastases or isolated bony metastases).

Pheochromocytoma and paraganglioma often express the somatostatin receptor proteins SSTR2 and SSTR3 which may allow for targeted treatment with somatostatin receptor agonists.[13,14] A meta-analysis of studies involving advanced or metastatic pheochromocytoma and paraganglioma patients treated with peptide receptor radionuclide therapy showed that 89.8% of pooled patients had achieved disease stabilization or a partial response.[15][Level of evidence C3]

Source links and citations

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice